---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Co-prescribed/Concomitant therapies. Topics: Discontinuation of prohibited medications before dosing in the phase 3 trials; Antidepressant discontinuation during screening in the phase 2b trial; Withdrawal of antidepressant, antipsychotic, and mood-stabilizing drugs in the PsiDeR trial; Adjunctive SSRI: COMP360 25 mg with an ongoing SSRI; 3 further topics. 7 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Discontinuation of prohibited medications before dosing in the phase 3 trials

> “At Screening, agreement to discontinue all prohibited medications.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.12-2"></a>

### Antidepressant discontinuation during screening in the phase 2b trial

> “Data from 233 participants with treatment-resistant depression (TRD) who received 25 mg, 10 mg, or 1 mg of investigational drug COMP360 psilocybin (a proprietary, pharmaceutical-grade synthetic psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.), administered with psychological support, were compared for groups of participants who either discontinued one or more antidepressant drugs during screening or entered the trial antidepressant drug free.”
> “Suicidality was comparable between groups at Baseline.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-2.1.2.12-3"></a>

### Withdrawal of antidepressant, antipsychotic, and mood-stabilizing drugs in the PsiDeR trial

> “during which they were withdrawn from antidepressant, antipsychotic or mood-stabilizing drugs and had sessions of psychological preparation and psychoeducation with a trial therapist”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-2.1.2.12-4"></a>

### Adjunctive SSRI: COMP360 25 mg with an ongoing SSRI

> “Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.”
> “All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.”
> “Twelve (63.2%) participants had a TEAE, most of which were mild and resolved on the day of onset.”
> “There were no serious TEAEs or indication of increased suicidal ideation or behavior.”
> “Larger, comparator-controlled trials are necessary to understand if this paradigm can optimize treatment-outcome where antidepressant drug withdrawal would be problematic.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

> “25mg COMP360 psilocybin treatment was generally well-tolerated when it was administered simultaneously with the patient’s existing SSRI treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.12-5"></a>

### Adjunctive antidepressant permitted in the company's PTSD trial

> “In both Part A and Part B, COMP360 may be administered adjunctively to a single permitted oral antidepressant.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.12-6"></a>

### Concomitant psychotherapy

> “Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study.”
> “Psychological therapies cannot have been initiated within 30 days prior to Screening”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy.”

Source: [COMPASS Pathways support model publication release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx)

> “As of the publication date of this guidance, the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.12-7"></a>

### Rescue medication during an administration session

> “An AE of substance induced psychotic disorder was reported for a participant who became behaviourally disinhibited during the acute drug experience.”
> “After a medical assessment, 2.5 mg oromucosal midazolam was administered.”
> “The participant recovered with no sequelae and was discharged 11 h after receiving the study intervention.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

Additional sources: [Goodwin et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37434509/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
